HELPING THE OTHERS REALIZE THE ADVANTAGES OF ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

In Section A, individuals will receive different doses and schedules of oral ABBV-744 pill to discover Protected dosing regimen. Supplemental members is going to be enrolled with the identified monotherapy dosign program. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Segment C, mem